Interleukin 12 shows a better curative effect on lung cancer than paclitaxel and cisplatin doublet chemotherapy

[1]  E. Lengyel,et al.  Metformin inhibits ovarian cancer growth and increases sensitivity to paclitaxel in mouse models. , 2015, American journal of obstetrics and gynecology.

[2]  Zhehai Wang.  Selection of chemotherapy for non-small cell lung cancer is facilitated by new therapeutic strategies. , 2014, International journal of clinical and experimental medicine.

[3]  L. Zitvogel,et al.  Cytokines reinstate NK cell-mediated cancer immunosurveillance. , 2014, The Journal of clinical investigation.

[4]  Lucas H. Horan,et al.  Cytokine therapy reverses NK cell anergy in MHC-deficient tumors. , 2014, The Journal of clinical investigation.

[5]  G. Calin,et al.  Hypoxia Mediated Downregulation of miRNA Biogenesis Promotes Tumor Progression , 2014, Nature Communications.

[6]  P. Tchounwou,et al.  Cisplatin in cancer therapy: molecular mechanisms of action. , 2014, European journal of pharmacology.

[7]  A. Rossi,et al.  Six versus fewer planned cycles of first-line platinum-based chemotherapy for non-small-cell lung cancer: a systematic review and meta-analysis of individual patient data. , 2014, The Lancet. Oncology.

[8]  D. Bae,et al.  Antiangiogenic Therapy with Human Apolipoprotein(a) Kringle V and Paclitaxel in a Human Ovarian Cancer Mouse Model12 , 2014, Translational oncology.

[9]  A. Sood,et al.  Dynamin 2 along with microRNA-199a reciprocally regulate hypoxia-inducible factors and ovarian cancer metastasis , 2014, Proceedings of the National Academy of Sciences.

[10]  S. Griffey,et al.  Antitumor Effects of Cisplatin Combined with Tecemotide Immunotherapy in a Human MUC1 Transgenic Lung Cancer Mouse Model , 2014, Cancer Immunology Research.

[11]  Z. Dong,et al.  Paclitaxel: new uses for an old drug , 2014, Drug design, development and therapy.

[12]  G. Dy,et al.  First line treatment of advanced non-small-cell lung cancer – specific focus on albumin bound paclitaxel , 2013, International journal of nanomedicine.

[13]  L. Bracci,et al.  Immune-based mechanisms of cytotoxic chemotherapy: implications for the design of novel and rationale-based combined treatments against cancer , 2013, Cell Death and Differentiation.

[14]  P. Lambin,et al.  Comparison of toxicity and outcomes of concurrent radiotherapy with carboplatin/paclitaxel or cisplatin/etoposide in stage III non–small cell lung cancer , 2013, Cancer medicine.

[15]  A. Jemal,et al.  Cancer statistics, 2013 , 2013, CA: a cancer journal for clinicians.

[16]  Dmitry I. Gabrilovich,et al.  Novel mechanism of synergistic effects of conventional chemotherapy and immune therapy of cancer , 2013, Cancer Immunology, Immunotherapy.

[17]  David Jarjoura,et al.  IL-12 Enhances the Antitumor Actions of Trastuzumab via NK Cell IFN-γ Production , 2011, The Journal of Immunology.

[18]  B. Becher,et al.  IL-12 initiates tumor rejection via lymphoid tissue–inducer cells bearing the natural cytotoxicity receptor NKp46 , 2010, Nature Immunology.

[19]  T. Ley,et al.  Interleukin 12 stimulates IFN-gamma-mediated inhibition of tumor-induced regulatory T-cell proliferation and enhances tumor clearance. , 2009, Cancer research.

[20]  M. Ashraf,et al.  Paclitaxel and immune system. , 2009, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[21]  M. Grever,et al.  A phase I trial of paclitaxel and trastuzumab in combination with interleukin-12 in patients with HER2/neu-expressing malignancies , 2009, Molecular Cancer Therapeutics.

[22]  A. Rapti,et al.  Comparison of cisplatin-paclitaxel combination versus cisplatin-etoposide in patients with small-cell lung cancer: a Phase III study. , 2008, Oncology reports.

[23]  S. Steinberg,et al.  Phase 2 study of pegylated liposomal doxorubicin in combination with interleukin-12 for AIDS-related Kaposi sarcoma. , 2007, Blood.

[24]  M. Del Vecchio,et al.  Interleukin-12: Biological Properties and Clinical Application , 2007, Clinical Cancer Research.

[25]  Emilie Flaberg,et al.  Effect of frequently used chemotherapeutic drugs on the cytotoxic activity of human natural killer cells , 2007, Molecular Cancer Therapeutics.

[26]  P. Alard,et al.  Reversing Tumor Immune Suppression with Intratumoral IL-12: Activation of Tumor-Associated T Effector/Memory Cells, Induction of T Suppressor Apoptosis, and Infiltration of CD8+ T Effectors1 , 2006, The Journal of Immunology.

[27]  M. Zeniya,et al.  Interferon-gamma produced by interleukin-12-activated tumor infiltrating CD8+T cells directly induces apoptosis of mouse hepatocellular carcinoma. , 2006, Journal of hepatology.

[28]  T. Mcclanahan,et al.  IL-23 promotes tumour incidence and growth , 2006, Nature.

[29]  G. Silvestri,et al.  One hundred years of lung cancer. , 2005, American journal of respiratory and critical care medicine.

[30]  Miklos Pless,et al.  Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[31]  F. Bussolino,et al.  IL-12 Regulates an Endothelial Cell-Lymphocyte Network: Effect on Metalloproteinase-9 Production1 , 2003, The Journal of Immunology.

[32]  G. Trinchieri,et al.  Interleukin-12 and the regulation of innate resistance and adaptive immunity , 2003, Nature Reviews Immunology.

[33]  D. Ruiter,et al.  Induction of vascular endothelial growth factor receptor-3 expression on tumor microvasculature as a new progression marker in human cutaneous melanoma. , 2002, Cancer research.

[34]  J. Norton,et al.  The role of IFN-γ in rejection of established tumors by IL-12: Source of production and target , 2002 .

[35]  J. Norton,et al.  The role of IFN-gamma in rejection of established tumors by IL-12 : source of production and target. , 2002, Cancer research.

[36]  T. Habermann,et al.  Phase 1 study of interleukin-12 in combination with rituximab in patients with B-cell non-Hodgkin lymphoma. , 2002, Blood.

[37]  J. Norton,et al.  Pre-Existing Tumor-Sensitized T Cells Are Essential for Eradication of Established Tumors by IL-12 and Cyclophosphamide Plus IL-121 , 2001, The Journal of Immunology.

[38]  A. Dowlati,et al.  Paclitaxel added to the cisplatin/etoposide regimen in extensive-stage small cell lung cancer -- the use of complete response rate as the primary endpoint in phase II trials. , 2001, Lung cancer.

[39]  K. Alitalo,et al.  Vascular endothelial growth factor receptor-3 in lymphangiogenesis in wound healing. , 2000, The American journal of pathology.

[40]  A. Jemal,et al.  Global cancer statistics , 2011, CA: a cancer journal for clinicians.

[41]  J. Teruya-Feldstein,et al.  Contribution of the CXC chemokines IP‐10 and Mig to the antitumor effects of IL‐12 , 1998, Journal of leukocyte biology.

[42]  S. Pestka,et al.  Tumor cell responses to IFNgamma affect tumorigenicity and response to IL-12 therapy and antiangiogenesis. , 1998, Immunity.

[43]  L. Schwartz,et al.  Phase I trial of subcutaneous recombinant human interleukin-12 in patients with advanced renal cell carcinoma. , 1998, Clinical cancer research : an official journal of the American Association for Cancer Research.

[44]  J. Norton,et al.  Immune response against large tumors eradicated by treatment with cyclophosphamide and IL-12. , 1998, Journal of immunology.

[45]  M. Del Vecchio,et al.  Pilot study of subcutaneous recombinant human interleukin 12 in metastatic melanoma. , 1998, Clinical cancer research : an official journal of the American Association for Cancer Research.

[46]  P. Ghezzi,et al.  Protective effect of a single interleukin-12 (IL-12) predose against the toxicity of subsequent chronic IL-12 in mice: role of cytokines and glucocorticoids. , 1997, Blood.

[47]  J. Leonard,et al.  Effects of Single-Dose Interleukin-12 Exposure on Interleukin-12–Associated Toxicity and Interferon-γ Production , 1997 .

[48]  J. Leonard,et al.  Effects of single-dose interleukin-12 exposure on interleukin-12-associated toxicity and interferon-gamma production. , 1997, Blood.

[49]  A. Angiolillo,et al.  Inhibition of angiogenesis by interleukin-12 is mediated by the interferon-inducible protein 10. , 1996, Blood.

[50]  J Cohen,et al.  IL-12 Deaths: Explanation and a Puzzle , 1995, Science.

[51]  R. Schreiber,et al.  Recombinant IL-12 administration induces tumor regression in association with IFN-gamma production. , 1994, Journal of immunology.

[52]  L. Luistro,et al.  Antitumor and antimetastatic activity of interleukin 12 against murine tumors , 1993, The Journal of experimental medicine.

[53]  Kenneth M. Murphy,et al.  Dendritic cells and macrophages are required for Th1 development of CD4+ T cells from αβ TCR transgenic mice: IL-12 substitution for macrophages to stimulate IFN-γ production is IFN-γ-dependent , 1993 .

[54]  Susanne A. Fischer,et al.  Interleukin‐12/T cell stimulating factor, a cytokine with multiple effects on T helper type 1 (Th1) but not on Th2 cells , 1993, European journal of immunology.

[55]  C. Hsieh,et al.  Dendritic cells and macrophages are required for Th1 development of CD4+ T cells from alpha beta TCR transgenic mice: IL-12 substitution for macrophages to stimulate IFN-gamma production is IFN-gamma-dependent. , 1993, International immunology.

[56]  F. Podlaski,et al.  Purification to homogeneity and partial characterization of cytotoxic lymphocyte maturation factor from human B-lymphoblastoid cells. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[57]  G. Trinchieri,et al.  Identification and purification of natural killer cell stimulatory factor (NKSF), a cytokine with multiple biologic effects on human lymphocytes , 1989, Journal of Experimental Medicine.

[58]  N. Dubrawsky.  Cancer statistics , 1989, CA: a cancer journal for clinicians.